$GILD · GILEAD SCIENCES, INC. SEC Filings
Position Tracker tracks 12 SEC EDGAR filings for GILEAD SCIENCES, INC. ($GILD) from September 2, 2026 through October 30, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 10 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$GILD 10-Q — GILEAD SCIENCES, INC.
The contrast between strong Q3 operating performance ($3.46B operating income) and the nine-month $6.0B GAAP loss from aggressive M&A illustrates both Gilead's growth ambitions…
$GILD 8-K — GILEAD SCIENCES, INC.
Gilead delivered its strongest base business growth in more than a decade while simultaneously absorbing $12.4B in pipeline-building M&A charges — a high-conviction bet on futur…
$GILD 4 — Gilead Sciences, Inc.
A Form 4 filing from Gilead Sciences, Inc. reports that Daniel O'Day, the company's Chairman and CEO, sold common stock on October 1, 2026. The filing indicates the transactions…
$GILD 4 — Gilead Sciences, Inc.
Gilead Sciences, Inc. filed a Form 4 with the SEC on September 23, 2026 reporting transactions by Erin Burkhart, the company’s Senior Vice President of Controllership. The filin…
$GILD 4 — Gilead Sciences, Inc.
This SEC Form 4 filing reports a change in beneficial ownership for Gilead Sciences, Inc. by Andrew D. Dickinson, the company's Chief Financial Officer. According to the filing,…
$GILD 4 — Gilead Sciences, Inc.
The filing is a SEC Form 4 from Gilead Sciences, Inc. It reports that Johanna Mercier, the company’s Chief Comm & Corp Aff Officer, sold shares of Gilead common stock on Septemb…
$GILD 4 — Gilead Sciences, Inc.
On September 10, 2026, Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., reported changes in his beneficial ownership of company stock on a Form 4 filing. H…
$GILD 4 — Gilead Sciences, Inc.
Gilead Sciences, Inc. filed a Form 4 on September 11, 2026, reporting transactions by Dietmar Berger, the company’s Chief Medical Officer. On September 10, 2026, Berger received…
$GILD 4 — Gilead Sciences, Inc.
On September 10, 2026, Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, Inc., reported changes in her beneficial ownership in a Form 4 filed with the SEC on Se…
$GILD 4 — Gilead Sciences, Inc.
On September 10, 2026, Keeley M. Cain Wettan, Executive Vice President, General Counsel, Legal & Compliance at Gilead Sciences, Inc., reported changes in her beneficial ownershi…
$GILD 4 — Gilead Sciences, Inc.
Gilead Sciences filed a Form 4 on September 11, 2026, reporting transactions by Daniel Patrick O'Day, the company's Chairman and Chief Executive Officer. The filing states that…
$GILD 4 — Gilead Sciences, Inc.
On September 2, 2026, Gilead Sciences, Inc. Chairman and CEO Daniel Patrick O’Day filed a Form 4 reporting changes in beneficial ownership. The filing shows that on September 1,…